Rigel Pharmaceuticals, Inc.  

(Public, NASDAQ:RIGL)   Watch this stock  
Find more results for RIGL
+0.55 (12.59%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.22 - 4.97
52 week 1.56 - 4.97
Open 4.82
Vol / Avg. 3.56M/736,293.00
Mkt cap 429.24M
P/E     -
Div/yield     -
EPS -1.04
Shares 88.05M
Beta 1.26
Inst. own 87%
May 5, 2015
Q1 2015 Rigel Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 3, 2015
Rigel Pharmaceuticals Inc at Cowen Health Care Conference
Mar 3, 2015
Q4 2014 Rigel Pharmaceuticals Inc Earnings Release
Feb 10, 2015
Rigel Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -269.96% -1101.91%
Operating margin -271.13% -1106.05%
EBITD margin - -964.70%
Return on average assets -56.30% -47.82%
Return on average equity -64.95% -54.03%
Employees 127 -
CDP Score - -


1180 Veterans Blvd
United States - Map
+1-650-6241100 (Phone)
+1-650-6241101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has five product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor expected to enter Phase 3 clinical trials for immune thrombocytopenic purpura (ITP) and a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator entering Phase 1 in the first half of 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS (BerGenBio) and Daiichi Sankyo (Daiichi), respectively.

Officers and directors

Raul R. Rodriguez President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ryan D. Maynard Chief Financial Officer and Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Donald G. Payan M.D. Executive Vice President, President - Discovery and Research, Director
Age: 66
Bio & Compensation  - Reuters
Elliott B. Grossbard M.D. Executive Vice President and Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Bradford S. Goodwin Independent Director
Age: 60
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 64
Bio & Compensation  - Reuters
Walter H. Moos Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter S. Ringrose Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Stephen A. Sherwin M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters